792 related articles for article (PubMed ID: 29368456)
1. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
2. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
3. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
[TBL] [Abstract][Full Text] [Related]
4. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
6. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
Corma-Gómez A; Macías J; Merino Muñoz D; Téllez F; Granados R; Morano LE; De Los Santos Gil I; Vera-Méndez FJ; Collado A; Palacios R; Pineda JA
J Infect; 2019 Jul; 79(1):30-35. PubMed ID: 31100364
[TBL] [Abstract][Full Text] [Related]
7. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
8. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
9. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
10. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
11. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
[TBL] [Abstract][Full Text] [Related]
13. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
15. Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
Deenen MJ; de Kanter CT; Dofferhoff AS; Grintjes-Huisman KJ; van der Ven AJ; Fleuren HW; Gisolf EH; Koopmans PP; Drenth JP; Burger DM
Ther Drug Monit; 2015 Dec; 37(6):751-5. PubMed ID: 26102531
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
17. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
18. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
19. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Martel-Laferrière V; Brinkley S; Bichoupan K; Posner S; Stivala A; Perumalswami P; Schiano T; Sulkowski M; Dieterich D; Branch A
HIV Med; 2014 Feb; 15(2):108-15. PubMed ID: 24025147
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
